Javascript must be enabled to continue!
RETROGRADE CORONARY VENOUS DELIVERY OF FIBROBLAST GROWTH FACTOR-2 ENHANCES IN VIVO HOMING AND DIFFERENTIATION OF MESENCHYMAL STEM CELLS
View through CrossRef
Objectives
In vitro studies showed fibroblast growth factor-2 (FGF-2) controls migration of mesenchymal stem cells (MSCs). In the present study, we established concentration gradient of FGF-2 between coronary venous blood and target myocardium by coronary venous retroperfusion and assessed the effects of FGF-2 gradient on in vivo homing and differentiation of MSCs.
Methods
Acute myocardial infarction (AMI) was induced by ligation of left anterior descending (LAD) coronary artery. First, twelve animals were randomised into 4 groups based on the time of balloon dilation (retroperfusion time), being 0 min (n=3), 5 min (n=3), 10 min (n=3), 15 min (n=3). One week after AMI, FGF-2 was retrogradely perfused into anterior interventricular vein in parallel to LAD, and FGF-2 concentrations of serum and myocardial tissue were measured by ELISA. The time of FGF-2 gradients after coronary venous retroperfusion was evaluated. Second, ten animals were randomised to MSCs group (n=5) and FGF-2+MSCs group (n=5) after AMI. MSCs were cultured and transfected by pLEGFP-N1 vector before transplantation. One week after retroperfusion, EGFP-positive endothelial cells and cardiomyocytes in infarcted myocardium were compared between the two groups by immunofluorescence method.
Results
First, there were statistical differences regarding FGF-2 concentration between coronary venous blood and infarcted myocardium at 5 min (81.13±15.07 pg/ml vs 210.66±65.09 pg/ml, p<0.05) and 10 min (59.80±12.15 vs 124.92±21.31, p<0.05). No difference was found between the two tissues at 15 min. Remarkable FGF-2 gradient can be established between coronary venous blood and infarcted myocardium at 5–10 min after retroperfusion. Second, FGF-2+MSCs group showed more EGFP-positive cells compared with MSCs group. The number of endothelial cells (23.8±6.2/mm2 vs 11.4±2.9/mm2, p<0.05) and cardiomyocytes (11.3±2.5/mm2 vs 8.3±2.2/mm2, p<0.05) originating from the injected cells was more in the FGF-2+MSCs group than in the MSCs group.
Conclusions
A stable FGF-2 concentration gradient can be established in vivo between coronary venous blood and infarcted myocardium at 5–10 min after retroperfusion, which can promote homing of MSCs into the infarcted myocardium and differentiation.
Title: RETROGRADE CORONARY VENOUS DELIVERY OF FIBROBLAST GROWTH FACTOR-2 ENHANCES IN VIVO HOMING AND DIFFERENTIATION OF MESENCHYMAL STEM CELLS
Description:
Objectives
In vitro studies showed fibroblast growth factor-2 (FGF-2) controls migration of mesenchymal stem cells (MSCs).
In the present study, we established concentration gradient of FGF-2 between coronary venous blood and target myocardium by coronary venous retroperfusion and assessed the effects of FGF-2 gradient on in vivo homing and differentiation of MSCs.
Methods
Acute myocardial infarction (AMI) was induced by ligation of left anterior descending (LAD) coronary artery.
First, twelve animals were randomised into 4 groups based on the time of balloon dilation (retroperfusion time), being 0 min (n=3), 5 min (n=3), 10 min (n=3), 15 min (n=3).
One week after AMI, FGF-2 was retrogradely perfused into anterior interventricular vein in parallel to LAD, and FGF-2 concentrations of serum and myocardial tissue were measured by ELISA.
The time of FGF-2 gradients after coronary venous retroperfusion was evaluated.
Second, ten animals were randomised to MSCs group (n=5) and FGF-2+MSCs group (n=5) after AMI.
MSCs were cultured and transfected by pLEGFP-N1 vector before transplantation.
One week after retroperfusion, EGFP-positive endothelial cells and cardiomyocytes in infarcted myocardium were compared between the two groups by immunofluorescence method.
Results
First, there were statistical differences regarding FGF-2 concentration between coronary venous blood and infarcted myocardium at 5 min (81.
13±15.
07 pg/ml vs 210.
66±65.
09 pg/ml, p<0.
05) and 10 min (59.
80±12.
15 vs 124.
92±21.
31, p<0.
05).
No difference was found between the two tissues at 15 min.
Remarkable FGF-2 gradient can be established between coronary venous blood and infarcted myocardium at 5–10 min after retroperfusion.
Second, FGF-2+MSCs group showed more EGFP-positive cells compared with MSCs group.
The number of endothelial cells (23.
8±6.
2/mm2 vs 11.
4±2.
9/mm2, p<0.
05) and cardiomyocytes (11.
3±2.
5/mm2 vs 8.
3±2.
2/mm2, p<0.
05) originating from the injected cells was more in the FGF-2+MSCs group than in the MSCs group.
Conclusions
A stable FGF-2 concentration gradient can be established in vivo between coronary venous blood and infarcted myocardium at 5–10 min after retroperfusion, which can promote homing of MSCs into the infarcted myocardium and differentiation.
Related Results
Stem cells
Stem cells
What is a stem cell? The term is a combination of ‘cell’ and ‘stem’. A cell is a major category of living thing, while a stem is a site of growth and support for something else. In...
Differential marker expression by cultures rich in mesenchymal stem cells
Differential marker expression by cultures rich in mesenchymal stem cells
AbstractBackgroundMesenchymal stem cells have properties that make them amenable to therapeutic use. However, the acceptance of mesenchymal stem cells in clinical practice requires...
Basic fibroblast growth factor promotes in vivo homing and differentiation of mesenchymal stem cells by coronary venous retroperfusion
Basic fibroblast growth factor promotes in vivo homing and differentiation of mesenchymal stem cells by coronary venous retroperfusion
Objective
To elucidate the mechanisms of combined myogenesis and angiogenesis using mesenchymal stem cells (MSCs) and basic fibroblast growth factor (bFGF), we es...
ANALISIS PERTIMBANGAN MAHKAMAH AGUNG DALAM MENGABULKAN KASASI TERDAKWA (STUDI PUTUSAN NOMOR 2959/K/PID.SUS/2022)
ANALISIS PERTIMBANGAN MAHKAMAH AGUNG DALAM MENGABULKAN KASASI TERDAKWA (STUDI PUTUSAN NOMOR 2959/K/PID.SUS/2022)
<p><em><span class="markedContent"><span style="left: calc(var(--scale-factor)*195.53px); top: calc(var(--scale-factor)*496.87px); font-size: calc(var(--scale-...
Myeloma Cell-Derived Runx2 Promotes Myeloma Progression and Bone-Homing
Myeloma Cell-Derived Runx2 Promotes Myeloma Progression and Bone-Homing
Abstract
Background. Multiple myeloma (MM), an incurable plasma-cell malignancy, preferentially grows in bone marrow and frequently metastasizes to new bone sites. T...
STEM CELLS IN VETERINARY MEDICINE – FROM BIOLOGY TO CLINIC
STEM CELLS IN VETERINARY MEDICINE – FROM BIOLOGY TO CLINIC
Mesenchymal stem cells are adult stem cells found in different adult tissues such as adipose tissue, bone marrow, and also in umbilical blood. Mesenchymal stem cells are capable of...
Myogenic-induced mesenchymal stem cells are capable of modulating the immune response by regulatory T cells
Myogenic-induced mesenchymal stem cells are capable of modulating the immune response by regulatory T cells
Cell therapy for patients who have intractable muscle disorders may require highly regenerative cells from young, healthy allogeneic donors. Mesenchymal stem cells are currently un...
Abstract 1488: Metastatic analysis of clonal epithelial and mesenchymal-like murine mammary tumor cells.
Abstract 1488: Metastatic analysis of clonal epithelial and mesenchymal-like murine mammary tumor cells.
Abstract
Tumor metastasis is the most common cause of cancer mortality, and yet it is among the most poorly understood processes in tumor progression. While carcinom...

